Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C CAR 168

Next Previous
Drug Profile

C CAR 168

Alternative Names: C-CAR-168; CD20/BCMA-directed CAR-T cell therapy - AbelZeta Pharma

Latest Information Update: 21 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbelZeta Pharma
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 15 Jan 2026 Huashan Hospital and Shanghai AbelZeta plans a phase I trial for Autoimmune disorder (Treatment-experienced) in February 2026 (IV) (NCT07341828)
  • 27 May 2025 AbelZeta plans to request a type B meeting with the US FDA to discuss the next steps in the clinical and manufacturing development of C CAR168
  • 27 May 2025 C CAR 168 receives Regenerative Medicine Advanced Therapy (RMAT) status for Systemic lupus erythematosus in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top